Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heplisav-B in Hepatitis B Vaccine Non-Responders
NCT04385524Withdrawn
- Sponsor
- University of Louisville
- Start
- Jun 2020
- Primary completion
- Feb 2021
- Modality
- Split/Subunit Vaccines, Recombinant Protein Vaccines
01
Overview
Open-label, single-arm trial of Hepatitis B vaccine in hepatitis B (HBV), sponsored by University of Louisville. Primary endpoint: Hepatitis B Seroconversion as Measured by Achievement of 10iU/ml on Quantitative Hepatitis B Titer at 3 months. Planned start Jun 2020; status: withdrawn.
02
Drugs
Hepatitis B vaccine
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT04385524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04385524.